Context Therapeutics Reports $26.7M Loss, Expands Cancer Pipeline with $94M Funding

Context Therapeutics Inc. has reported its financial results in its annual Form 10-K for the fiscal year ended December 31, 2024, revealing a net loss of $26.7 million, an increase from the previous year's loss. The company is focusing on T cell engaging bispecific antibodies for solid tumors, with product candidates CTIM-76, CT-95, and CT-202 advancing through various stages of clinical trials. CTIM-76 has entered a Phase 1 trial, and CT-95 is expected to begin its trial in mid-2025, with initial data anticipated for CTIM-76 in early 2026. Research and development expenses rose to $22.7 million, primarily due to costs associated with these candidates. Context Therapeutics ended the year with $94.4 million in cash, projected to fund operations through 2027, and plans to seek additional capital for ongoing development. The company's strategic acquisitions and leadership enhancements aim to strengthen its position in the competitive biopharmaceutical market.